KLDO (Kaleido Biosciences) Other Current Assets: $3.84 Mil (As of Dec. 2021)


What is Kaleido Biosciences Other Current Assets?

Kaleido Biosciences KLDO Other Current Assets is $3.84 Mil as of Dec. 2021.

Kaleido Biosciences's other current assets for the quarter that ended in Dec. 2021 was $3.84 Mil.

Kaleido Biosciences's quarterly other current assets increased from Jun. 2021 ($2.62 Mil) to Sep. 2021 ($2.65 Mil) and increased from Sep. 2021 ($2.65 Mil) to Dec. 2021 ($3.84Mil).

Kaleido Biosciences's annual other current assets increased from Dec. 2019 ($2.04 Mil) to Dec. 2020 ($2.50 Mil) increased from Dec. 2020 ($2.50 Mil) to Dec. 2021 ($3.84 Mil).


Kaleido Biosciences Other Current Assets Related Terms


Kaleido Biosciences Other Current Assets Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Other Current Assets Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Other Current Assets
Get a 7-Day Free Trial 0.05 0.16 2.04 2.50 3.84

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 2.67 2.62 2.65 3.84

Kaleido Biosciences Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $3.84 Mil mean?
Kaleido Biosciences (KLDO) has a Other Current Assets of $3.84 Mil as of Dec. 2021. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Kaleido Biosciences.
Is Kaleido Biosciences' Other Current Assets too high?
Kaleido Biosciences' current Other Current Assets is $3.84 Mil.
How does Kaleido Biosciences' Other Current Assets compare to NPTX and GSTC?
Kaleido Biosciences' Other Current Assets of $3.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Kaleido Biosciences. Kaleido Biosciences's current Other Current Assets is $3.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Other Current Assets of $3.84 Mil. The current Other Current Assets is $3.84 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Other Current Assets is $3.84 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.